Effects of oral iron chelator deferasirox on human malignant lymphoma cells
نویسندگان
چکیده
منابع مشابه
Effects of oral iron chelator deferasirox on human malignant lymphoma cells
BACKGROUND Iron is essential for cell proliferation and viability. It has been reported that iron depletion by a chelator inhibits proliferation of some cancer cells. Deferasirox is a new oral iron chelator, and a few reports have described its effects on lymphoma cells. The goal of this study was to determine the anticancer effects of deferasirox in malignant lymphoma cell lines. METHODS Thr...
متن کاملEffects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma
AIM To evaluate the inhibitory effects of deferasirox (DFX) against hepatocellular carcinoma (HCC) through basic and clinical studies. METHODS In the basic study, the effect of DFX was investigated in three hepatoma cell lines (HepG2, Hep3B, and Huh7), as well as in an N-nitrosodiethylamine-induced murine HCC model. In the clinical study, six advanced HCC patients refractory to chemotherapy w...
متن کاملDeferasirox: a novel, once-daily oral iron chelator
10.1586/14750708.3.4.453 © 2 Regular blood transfusions for the treatment of chronic anemia inevitably lead to iron overload since humans do not possess a physiological mechanism for removing excess iron. Without appropriate treatment, the cumulative effects of iron overload lead to severe organ damage and, ultimately, death. The iron chelating agent, deferoxamine, has been used effectively for...
متن کاملDeferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib
Although sorafenib is expected to have a chemopreventive effect on hepatocellular carcinoma (HCC) recurrence, there are limitations to its use because of adverse effects, including effects on liver function. We have reported that the iron chelator, deferoxamine can prevent liver fibrosis and preneoplastic lesions. We investigated the influence of administering a new oral iron chelator, deferasi...
متن کاملImmunological evaluation of β-thalassemia major patients receiving oral iron chelator deferasirox.
OBJECTIVE To determine the immune abnormalities and occurrence of infections in transfusion-dependent β-thalassemia major patients receiving oral iron chelator deferasirox (DFX). STUDY DESIGN An observational study. PLACE AND DURATION OF STUDY Hematology Clinics, King Khalid University Hospital, Riyadh, Saudi Arabia, from July to December 2010. METHODOLOGY Seventeen patients with β-thalas...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Korean Journal of Hematology
سال: 2012
ISSN: 1738-7949,2092-9129
DOI: 10.5045/kjh.2012.47.3.194